Erlotinib Completed Phase 2 Trials for Renal Cancers Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00425386Sunitinib and Erlotinib in Treating Patients With Unresectable or Metastatic Kidney Cancer
NCT00193154OSI-774 and Bevacizumab in the Treatment of Patients With Metastatic Renal Cell Carcinoma